EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth

A-Young Nam, Sang Hoon Joo, Na Yeong Lee, Goo Yoon, Jin Woo Park iD, MinKyun Na, Jung-Hyun Shim iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0329706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von A-Young Nam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Health and Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan, Republic of Korea. Hauptthemen laut MEDLINE: ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths, remaining a significant challenge in terms of early detection, effective treatment, and improving patient survival rates. In this study, we investigated the anticancer mechanism of rubiarbonol B (Ru-B) and its derivative 3- O -acetylrubiarbonol B (ARu-B), a pentacyclic terpenoid in gefitinib (GEF)-sensitive and -resistant NSCLC HCC827 cells. Concentration- and time-dependent cytotoxicity was observed for both Ru-B and ARu-B. The in vitro kinase assay showed that ARu-B treatment inhibited epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition (MET), and AKT1, and their phosphorylation in HCC827 cells. A molecular docking model suggested that ARu-B could interact with EGFR and MET in different ways, either by binding to the ATP pocket or the substrate pocket. ARu-B induced reactive oxygen species (ROS) generation and cell cycle arrest. The induction of apoptosis through caspase activation was confirmed by preventing cytotoxicity with Z-VAD-FMK pretreatment. Taken together, ARu-B inhibited the growth of both GEF-sensitive and GEF-resistant NSCLC cells by targeting EGFR, MET, and AKT and inducing ROS generation and caspase activation. Further studies on ARu-B can improve the treatment of chemotherapy-resistant NSCLC through the development of effective ARu-B-based anticancer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metDiterpenesAntineoplastic AgentsHumansCell Line, TumorCell ProliferationApoptosisMolecular Docking SimulationReactive Oxygen SpeciesProto-Oncogene Proteins c-aktPhosphorylationGefitinibCell Cycle CheckpointsChrysenes

Substanzen

ErbB ReceptorsProto-Oncogene Proteins c-metEGFR protein, humanMET protein, humanDiterpenesReactive Oxygen SpeciesAntineoplastic AgentsProto-Oncogene Proteins c-aktGefitinibrubiarbonol B

Autor:innen und Institutionen

  • Department of Biomedicine, Health and Life Convergence Sciences, BK21 Four, College of Pharmacy, Mokpo National University, Muan, Republic of Korea.
  • College of Pharmacy, Daegu Catholic University, Gyeongsan, Republic of Korea.
  • Department of Pharmacy, College of Pharmacy, Mokpo National University, Muan, Republic of Korea.
  • College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
  • The China-US (Henan) Hormel Cancer Institute, Zhengzhou, People's Republic of China.

ORCID-Profile: Jin Woo Park, Jung-Hyun Shim

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Nam, A. Y., Joo, S. H., Lee, N. Y., Yoon, G., Park, J. W., Na, M., & Shim, J. H. (2025). 3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. PLOS One. https://doi.org/10.1371/journal.pone.0329706

Vancouver

Nam AY, Joo SH, Lee NY, Yoon G, Park JW, Na M, et al. 3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth. PLOS One. 2025. doi:10.1371/journal.pone.0329706

BibTeX
@article{Nam2025,
  author = {Nam, A-Young and Joo, Sang Hoon and Lee, Na Yeong and Yoon, Goo and Park, Jin Woo and Na, MinKyun and Shim, Jung-Hyun},
  title = {3-O-acetylrubiarbonol B preferentially targets EGFR and MET over rubiarbonol B to inhibit NSCLC cell growth},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0329706}
}
Kostenlos starten →